Biological effects of NODAL on endometrial cancer cells and its underlying mechanisms. 2021

Xiaoshan Hong, and Bin Wen, and Huaming Zhang, and Yuhan Li, and Hengying Wu, and Wei Zhao, and Xiping Luo
Department of Gynecology, Guangdong Women and Children Hospital, Guangzhou, Guangdong 510010, P.R. China.

Activin A receptor type 1C (ALK7) and its ligand nodal growth differentiation factor (NODAL) serve numerous roles in cancer cells, including regulating cancer invasion, migration and apoptosis. NODAL promotes breast cancer cell apoptosis by activating ALK7; however, ALK7 and NODAL expression in endometrial cancer (EC), as well as their effects and underlying mechanisms in EC cells, are not completely understood. The present study aimed to characterize the expression of NODAL and ALK7 in EC, as well as the underlying mechanisms. The expression levels of ALK7 and NODAL were detected via reverse transcription-quantitative PCR and western blotting. Cell transfection was performed to overexpress NODAL or interfere ALK7. Cell proliferation, invasion and migration were detected via Cell Counting Kit-8, Transwell and wound healing assays, respectively. Flow cytometry was performed to detect cell apoptosis and western blotting was conducted to detect the expression levels of apoptosis-related proteins. NODAL and ALK7 expression levels were significantly decreased in EC cell lines compared with normal endometrial cells. NODAL overexpression inhibited EC cell proliferation, invasion and migration, and promoted EC cell apoptosis compared with the overexpression-negative control (Ov-NC) group. Moreover, NODAL overexpression significantly increased ALK7 expression levels in EC cells compared with the Ov-NC group. ALK7 reversed NODAL overexpression-mediated inhibition of EC cell proliferation, invasion and migration, and promotion of EC cell apoptosis. The present study indicated that NODAL inhibited EC cell proliferation, invasion and migration, and promoted EC cell apoptosis by activating ALK7.

UI MeSH Term Description Entries

Related Publications

Xiaoshan Hong, and Bin Wen, and Huaming Zhang, and Yuhan Li, and Hengying Wu, and Wei Zhao, and Xiping Luo
January 2024, Hematology, transfusion and cell therapy,
Xiaoshan Hong, and Bin Wen, and Huaming Zhang, and Yuhan Li, and Hengying Wu, and Wei Zhao, and Xiping Luo
January 2015, Advances in neurobiology,
Xiaoshan Hong, and Bin Wen, and Huaming Zhang, and Yuhan Li, and Hengying Wu, and Wei Zhao, and Xiping Luo
January 2006, Annual review of nutrition,
Xiaoshan Hong, and Bin Wen, and Huaming Zhang, and Yuhan Li, and Hengying Wu, and Wei Zhao, and Xiping Luo
December 2019, Biomolecules,
Xiaoshan Hong, and Bin Wen, and Huaming Zhang, and Yuhan Li, and Hengying Wu, and Wei Zhao, and Xiping Luo
October 2015, Molecular cancer therapeutics,
Xiaoshan Hong, and Bin Wen, and Huaming Zhang, and Yuhan Li, and Hengying Wu, and Wei Zhao, and Xiping Luo
September 1994, The Journal of clinical endocrinology and metabolism,
Xiaoshan Hong, and Bin Wen, and Huaming Zhang, and Yuhan Li, and Hengying Wu, and Wei Zhao, and Xiping Luo
April 2020, Rejuvenation research,
Xiaoshan Hong, and Bin Wen, and Huaming Zhang, and Yuhan Li, and Hengying Wu, and Wei Zhao, and Xiping Luo
January 2021, Current pharmaceutical design,
Xiaoshan Hong, and Bin Wen, and Huaming Zhang, and Yuhan Li, and Hengying Wu, and Wei Zhao, and Xiping Luo
November 2015, Experimental neurology,
Xiaoshan Hong, and Bin Wen, and Huaming Zhang, and Yuhan Li, and Hengying Wu, and Wei Zhao, and Xiping Luo
February 2024, Biochemical genetics,
Copied contents to your clipboard!